Efficacy of Paclitaxel and S-1 in a Patient with Advanced Pseudomyxoma Peritonei Concomitant with Gastric Cancer

Yukako Mokutani¹, Junichi Nishimura¹, Mamoru Uemura¹, Naotsugu Haraguchi², Tarou Hayashi², Taishi Hata¹, Ichiro Takemasa¹, Tsunekazu Mizushima¹, Masanori Kishibuchi², Hirofumi Yamamoto²*, Yuichiro Doki¹ and Masaki Mori³

¹Department of Surgery, Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Japan
²Medical Corporation Yukoukai, Saito Yukoukai Hospital, Japan
³Department of Surgery, Shitennoji Hospital, Japan

Abstract

Pseudomyxoma Peritonei (PMP) is a rare disease characterized by disseminated intra-peritoneal implants and mucinous ascites. There is currently no standard treatment strategy for PMP.

Presentation of case: We present an unusual case of advanced PMP concomitant with early gastric cancer in a 61-year-old male. In the first operation, in December 2007, the gastric cancer was unrespectable by extensive dissemination of PMP. Therefore, cytoreductive surgery for PMP and appendectomy were performed. After systemic chemotherapy with paclitaxel (Taxol, PTX) plus S-1 for almost 1 year, the dissemination on the stomach and intestines disappeared, and we were able to perform a subtotal gastrectomy to remove early gastric cancer. Afterwards, with the intermittent administration of irinotecan (CPT-11) in addition to the basal use of S-1, the patient survived more than five years. To the present day, systemic therapy is still being administered, and might lead to stabilization of disease.

Keywords: Pseudomyxoma peritonei; Chemotherapy; Gastric cancer

Introduction

Pseudomyxoma peritonei (PMP) is a rare disease characterized by disseminated intra-peritoneal implants and mucinous ascites. Although there is currently no standard treatment strategy for PMP, resection of the primary lesion and the removal of mucinous material are considered the most effective. However, in most cases complete excision is difficult, and various treatments are attempted, including chemotherapy. Here we present an atypical case of PMP that was concurrent with early gastric cancer. The patient could survive after surgical treatments and systemic chemotherapy.

Figure 1: Enhanced abdominal CT scans throughout treatment. (a) Before the first operation. (b) After chemotherapy, demonstrating the reduction of ascites. (c) Before the third operation.

Case presentation

A 61-year-old male underwent surgery for a left inguinal hernia in 2003 at another hospital, and mucinous ascites was detected at that time. No treatment was administered. In September 2007, abdominal distention appeared and abdominal computed tomography (CT) revealed edmassive mucinous ascites with septations and a partially scalloping spleen, which were characteristic of PMP (Figure 1a). Gastrointestinal endoscopy uncovered early gastric cancer.

In December 2007, surgery was executed for both gastric cancer and PMP. However, observing multiple peritoneal implants and dissemination to the stomach and small intestinal walls, the radical surgery to excise the gastric cancer was cancelled, and appendectomy, excision of the greateromentum, and incomplete cytoreduction were performed to treat the PMP. From pathological findings, we diagnosed the PMP as originating from the appendix (Figure 2).

After the PMP operation, the patient received 8 cycles of systemic chemotherapy with S-1120 mg/body (2 weeks on continuous medication and 2 weeks off) and paclitaxel (Taxol, PTX) 80 mg/m² (on days 1 and 15). Owing to the adverse event of peripheral neuropathy for PTX, the regimen was changed from PTX to irinotecan (CPT-11) 80 mg/m² (on days 1 and 15) with S-1 120 mg/body (3 weeks on continuous medication and 2 weeks off) for 3 weeks. We considered that S-1 was still effective, and therefore we continued basal use of S-1. After almost 1 year of systemic chemotherapy, CT showed that mucinous ascites

*Corresponding author: Hirofumi Yamamoto, Department of Surgery, Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamada-o, Suita City, Osaka, 565-0871, Japan, Tel: +81-6-6879-3251; Fax: +81-6-6879-3259; E-mail: hyamamoto@gesurg.med.osaka-u.ac.jp

Received August 28, 2013; Accepted October 25, 2013; Published October 31, 2013

Copyright: © 2013 Mokutani Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
lymph node metastasis and vascular invasion.

well-differentiated adenocarcinoma of with mucosal invasion, without

disappeared, and we were able to perform a subtotal gastrectomy

perform surgery to treat gastric cancer in January 2009.

embylonic antigen (CEA) level was reduced by a large margin (Figure

were remarkably decreased (Figure 1b) and the patient’s serum carcino

Figure 2: The mucinous epithelium of the appendix displayed minimal
cytological atypia and mitotic activity to warrant a diagnosis of mucinous
cystadenoma (hematoxylin/eosin staining, ×100 magnification).

Figure 3: A schematic depiction of therapeutic interventions and the dynamics
of CEA.

Figure 4: Operation findings. (a) The patient’s abdomen was distended
because of mucinous ascites. (b) The weight of the resected mucinous
materials was 2074 g.

were remarkably decreased (Figure 1b) and the patient’s serum carcino
embryonic antigen (CEA) level was reduced by a large margin (Figure
3). We judged that systemic chemotherapy was effective and decided to
perform surgery to treat gastric cancer in January 2009.

During the cancer operation, we found that the previous dissemination on the stomach and small intestinal walls had disappeared, and we were able to perform a subtotal gastrectomy according to the standard protocol. Pathological findings indicated well-differentiated adenocarcinoma of with mucosal invasion, without lymph node metastasis and vascular invasion.

After the operation, the patient received a regimen of 5 cycles
of S-1120 mg/body (4 weeks on medication and 2 weeks off) with
intermittent administration of CPT-1180 mg/m² (on days 1and 15) from
April 2009 to May 2010. After that, he received only oral chemotherapy:
3 cycles of S-1 120 mg/body (4 weeks on medication and 2 weeks off).

There was no evidence of any recurrence or metastasis of gastric
cancer; however, abdominal distention worsened because of PMP
growth (Figure 1c), and a third operation was performed in 2013. At
that time, the patient’s CEA level was up to 79 mg/ml. During the third
operation, we observed massive mucinous materials in the abdominal
cavity, as well as scalloping of the liver lateral segment region and
spleen (Figure 4a, b). We removed as much of the mucinous material
as possible. There were no postoperative complications. At present
(August 2013), the patient has received S-1 alone and the PMP is stable
and asymptomatic.

Discussion

PMP is revealed by the appearance of abdominal distention and
a new-onset inguinal hernia, or in the timing of surgery for acute-appendicitis in many cases [1]. Complete cytoreduction by surgery certainly improves the prognosis of the patients with PMP [2].

As cytoreductive surgical de-bulking procedures, Sugar baker proposed extensive peritoneectomy including greater omentectomy-splenectomy, stripping of the left and right hemi diaphragm, cholecystectomy and lesser omentectomy, antrectomy, and pelvic peritoneectomy with resection of the rectosigmoid colon. However, this procedure is associated with a high complication rate, and the safety and efficacy
of the procedure are uncertain [3]. Although Miner et al. [4] reported that complete excision of PMP was possible in 53 cases among 97 patients (55%), the rate of recurrence in those 53 cases was 91% at a
median follow-up period of 24 months. Treatment based on complete cytoreductive surgery with hypothermic intraperitoneal chemotherapy (HIPEC) may improve the prognosis. Using mitomycin C, CPT-11, and oxaliplat in for intraperitoneal chemotherapy with intravenous perfusion of 5-fluorouracil (5-FU) and leucovorin, Elias et al. [5] reported that the disease recurrence decreased to 26% when administered as HIPEC.

Sugarbaker’s new standard protocol of complete cytoreduction with HIPEC [2] results in a 20-year survival rate of 70%. However; there is no strategy for managing advanced PMP with metastases or with gross residual disease after cytoreductive surgery. Although conventional systemic chemotherapy did not improve the prognosis of PMP [6], a couple of cases have achieved long-term stabilization of PMP disease after incomplete cytoreduction using oxaliplatin/fluorouracil/leucovorin (FOLFOX4) [7] or bevacizumab with capectabine [8].

In the present case, combination of S-1 and PTX surely helped to remove gastric cancer after incomplete cytoreductive surgery; we observed that the disseminated tumor cells that were spread extensively on the gastric and intestinal walls had disappeared at the second
operation. Administration of PTX provides effective control of malignant ascites. The concentration of PTX in ascites is maintained within the optimal level for the treatment of cancer cells for up to 72 h after intravenous administration [9]. Moreover, the effect of S-1is also expected, as a previous study demonstrated a successful outcome with capectabine, apro-drug of 5-FU [10]. In that exploration, a phase study evaluating the use of concurrent mitomycin C and capectabine in patients with advanced unrespectable PMP, 15 of 39 assessable patients (38%) benefited from the chemotherapy regimen, which resulted in either reductions in mutinous deposition or stabilization of progression.

Serum CEA is often useful to evaluate the efficacy of therapy in patients with PMP in many cases [11]. In our case, CEA level was...
also useful for following disease progression. Judging from CEA level, from April 2009 to May 2010 (between the second and third operation), the combination of S-1 and CPT-11 was apparently more effective for disease control than S-1 alone (Figure 3). Every dose of CPT-11 decreased the rising CEA level. Almost 1 year of intermittent administration of CPT-11 in addition to the basal use of S-1 led to the stabilization of CEA level. The effect of CPT-11 in PMP treatment is reportedly limited to the HIPEC procedure; CPT-11 has been employed at concentrations of 100-360 mg/m2 [5,12]. The 80 mg/m2 dose of CPT-11 by intravenous injection with S-1 led to disease stabilization, and had no adverse events. Our regimen of CPT-11 combined with S-1 is based on our previous study [13] of advanced and recurrent colorectal cancer, and was changed to prolonged S-1 administration to improve the patient’s tolerance. Although the effect of systemic chemotherapy on PMP remains questionable, we suggest that systemic chemotherapy might be considered in a palliative setting for patients with recurrent or advanced disease.

It is rare to have other cancer at the same time as PMP [14]. While researching the origin of PMP, we should be careful regarding the possibility of other concomitant cancer. Moreover, we should consider multidisciplinary treatment when it is impossible to treat both PMP and a concomitant cancer in a single operation.

More clinical experience and additional studies are needed to determine the benefit of systemic chemotherapy. This case report emphasizes the efficacy of S-1 plus PTX or CPT-11 as systemic chemotherapy against advanced PMP.

Author Contributions

Hirofumi YAMAMOTO performed the operation and provided substantial information regarding the patient’s case. All authors have read and approved the final manuscript.

References

1. Moran BJ, Cecil TD (2003) The etiology, clinical presentation, and management of pseudomyxoma peritonei. Surg Oncol Clin N Am 12: 585-603.
2. Sugarbaker PH (2006) New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome. Lancet Oncol 7: 69-76.
3. Bryant J, Clegg AJ, Sidhu MK, Brodin H, Royle P, et al. (2005) Systematic review of the Sugarbaker procedure for pseudomyxoma peritonei. Br J Surg 92: 153-158.
4. Minier TJ, Shia J, Jaques DP, Klimstra DS, Brennan MF, et al. (2005) Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg 241: 300-308.
5. Elias D, Honoré C, Clucherdée R, Billard V, Raynard B, et al. (2008) Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Br J Surg 95: 1164-1171.
6. Smith JW, Kemeny N, Caldwell C, Banner P, Sigurdson E, et al. (1992) Pseudomyxoma peritonei of appendiceal origin. The Memorial Sloan-Kettering Cancer Center experience. Cancer 70: 396-401.
7. Chen CF, Huang CJ, Kang WY, Hsieh JS (2008) Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin/fluorouracil/leucovorin (FOLFOX4). World J Surg Oncol 6: 118.
8. Sun WL, Hutarew G, Gradi J, Gratzl M, Denz H, et al. (2009) Successful antiangiogenic combination therapy for pseudomyxoma peritonei with bevacizumab and capecitabine. Cancer Biol Ther 8: 1459-1462.
9. Kobayashi M, Sakamoto J, Namikawa T, Okamoto K, Okabayashi T, et al. (2006) Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients. World J Gastroenterol 12: 1412-1415.
10. Farquharson AL, Pranesh N, Witham G, Swindell R, Taylor MB, et al. (2008) A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei. Br J Cancer 99: 591-596.
11. van Ruth S, Hart AA, Bonfrer JM, Verwaal VJ, Zoetmulder FA (2002) Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy Ann Surg Oncol 10: 961-967.
12. Cotte E, Passot G, Tod M, Bakrin N, Gilly FN, et al. (2011) Closed abdomen hyperthermic intraperitoneal chemotherapy with irinotecan and mitomycin C: a phase I study. Ann Surg Oncol 18: 2599-2603.
13. Hata T, Fukunaga M, Murata K, Uemura Y, Fukuzaki T, et al. (2013) A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer. Cancer Chemother Pharmacol 71: 1657-1663.
14. Ikejiri K, Anai H, Kitamura K, Yakabe S, Saku M, et al. (1996) Pseudomyxoma peritonei concomitant with early gastric cancer: report of a case. Surg Today 26: 923-925.